Aethlon Medical grants James B. Frakes 42,000 stock units

The grant vests over one year subject to continued service, with full vesting upon closing of Aethlon's proposed merger with North Immunology.

Rhea-AI Filing Summary

Aethlon Medical Inc. (AEMD) director and CFO/CEO James B. Frakes received 42,000 restricted stock units (RSUs) under the company's 2020 Equity Incentive Plan. The RSUs vest over the one-year period following October 8, 2026, subject to continued service, and become fully vested upon closing of the proposed merger with North Immunology, Inc. Each RSU represents a contingent right to receive one common share upon settlement. His reported direct holdings following the grant were 42,063 shares.

Insider Trade Summary

Grant/Award: 42,000 shares

Grant/Award 1 txn

Insider FRAKES JAMES B

Role CFO/CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	42,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 42,063 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of 42,000 restricted stock units ("RSUs") pursuant to the Issuer's 2020 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest over the one-year period following October 8, 2026, subject to the Reporting Person's continued service through the applicable vesting dates. Notwithstanding the foregoing, the RSUs will become fully vested upon the closing of the Issuer's proposed merger with North Immunology, Inc.

Key Figures

Restricted stock units granted: 42,000 RSUs Common shares per RSU: 1 common share Vesting period: 1 year +1 more

4 metrics

Restricted stock units granted 42,000 RSUs Grant dated October 8, 2026

Common shares per RSU 1 common share Upon settlement

Vesting period 1 year Following October 8, 2026, subject to continued service

Reported direct holdings following transaction 42,063 shares Following the grant

Key Terms

restricted stock units, contingent right, 2020 Equity Incentive Plan, fully vested

4 terms

restricted stock units technical

"grant of 42,000 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right technical

"Each RSU represents a contingent right to receive one share"

2020 Equity Incentive Plan technical

"pursuant to the Issuer's 2020 Equity Incentive Plan"

fully vested technical

"the RSUs will become fully vested upon the closing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AEMD RSUs did CFO/CEO James B. Frakes receive?

James B. Frakes received 42,000 RSUs. The grant was made under Aethlon Medical Inc.'s 2020 Equity Incentive Plan, and each RSU represents a contingent right to receive one common share upon settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 09:14 PM EDT Accepted by SEC EDGAR 10/13/2026 - 09:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRAKES JAMES B

(Last) (First) (Middle)

11555 SORRENTO VALLEY ROAD, SUITE 203

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AETHLON MEDICAL INC [ AEMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO/CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/08/2026		A		42,000(1)	A	$0.00	42,063	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of 42,000 restricted stock units ("RSUs") pursuant to the Issuer's 2020 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest over the one-year period following October 8, 2026, subject to the Reporting Person's continued service through the applicable vesting dates. Notwithstanding the foregoing, the RSUs will become fully vested upon the closing of the Issuer's proposed merger with North Immunology, Inc.

	/s/ James B. Frakes	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)